"The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC" takes up the trial that the panel calls the biggest ...
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease ...
Core immunosuppressive regimens used to treat autoimmune hepatitis (AIH) have distinct patterns of reported adverse drug ...
Subcutaneous mosunetuzumab replaced the IV infusion for patients with R/R LBCL; 57.5% had mostly mild injection-site ...
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with ...
In "Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC," our experts confront a stubborn disconnect ...
The law, formally the One Big Beautiful Bill Act (Public Law 119-21) and now called the Working Families Tax Cuts legislation ...
HS is far more common than most clinicians realize, and its origins are multifactorial. Understanding genetic, mechanical, ...
Dyshidrotic eczema behaves differently from other forms of hand eczema in ways that matter for how it is worked up and ...
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in ...
Cancer survivors are living longer, but longer survival brings a new pressing question: who helps them live well afterward?
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
A UPL is the maximum reimbursement certain payers can provide pharmacies and providers for a drug. A UPL caps what a payer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results